Sorafenib is an oral multikinase inhibitor that inhibits tumor growth and proliferation by interfering with several receptor tyrosine kinases involved in the pathogenesis and perpetuation of ...

Purpose: The role of sunitinib and sorafenib in the treatment of metastatic renal cell carcinoma (mRCC) is reviewed. Conclusion: The tyrosine kinase inhibitors sorafenib and sunitinib offer ...

The immunotherapy combination significantly improved overall survival compared with lenvatinib or sorafenib. The Food and Drug Administration (FDA) has approved Opdivo ® (nivolumab) in ...